AstraZeneca Seeks F.D.A. Approval for Covid Antibody Treatment

The company said the treatment cuts the risk of symptomatic Covid in people who have conditions that put them at high risk and those who have not responded well to a vaccine.The company said the treatment cuts the risk of symptomatic Covid in people who have conditions that put them at high risk and those who have not responded well to a vaccine.

Leave a Reply